VePesid® / Toposar®
Etoposide is a topoisomerase II inhibitor derived from podophyllotoxin. Used in small cell lung cancer, testicular cancer, and lymphomas.
| Dosage Form | IV Injectable (Solution) / Oral Capsule |
| Strength | 20 mg/mL (IV); 50 mg capsules |
| Storage | Store at 20–25°C. Diluted solution stable for 96 hours at 25°C. |
| Category | Oncology |
| Availability | Available for Transfer |
Refractory testicular tumors (with other agents); small cell lung cancer (first-line with cisplatin).
Forms a complex with topoisomerase II and DNA, preventing DNA religation and causing double-strand breaks that trigger apoptosis.
Each Burrard Pharmaceuticals technology transfer package for Etoposide includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.